WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - SWISS RE/ZURICH INSURANCE/ROCHE GS/NOV... Share Price

Certificat

KNZTDU

CH1253178870

Market Closed - Bid/Ask 08:50:00 17/05/2024 pm IST After market 08:45:01 pm
100.1 CHF +0.10% Intraday chart for WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - SWISS RE/ZURICH INSURANCE/ROCHE GS/NOV... 100.4 +0.27%
1 month+0.55%
3 months+0.20%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Static data

Product typeAktienanleihen
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KNZTDU
ISINCH1253178870
Date issued 12/04/2023
Strike 275.4 CHF
Maturity 14/10/2024 (90 Days)
Parity 0.28 : 1
Emission price 100 CHF
Emission volume N/A
Settlement Beides
Currency CHF

Technical Indicators

Highest since issue 100.5 CHF
Lowest since issue 97.45 CHF
Spread 10.5 CHF
Spread %1.04%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.9 CHF
Average target price
274 CHF
Spread / Average Target
+5.83%
Consensus
  1. Stock Market
  2. Certificates
  3. KNZTDU Certificat